<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6160582</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.02123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Clinical Trial</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Efficacy of Lactoferrin Oral Administration in the Treatment of Anemia and Anemia of Inflammation in Pregnant and Non-pregnant Women: An Interventional Study </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lepanto</surname><given-names>Maria Stefania</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/428504/overview"/></contrib><contrib contrib-type="author"><name><surname>Rosa</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/428503/overview"/></contrib><contrib contrib-type="author"><name><surname>Cutone</surname><given-names>Antimo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/428507/overview"/></contrib><contrib contrib-type="author"><name><surname>Conte</surname><given-names>Maria Pia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Paesano</surname><given-names>Rosalba</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Valenti</surname><given-names>Piera</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/428500/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Public Health and Infectious Diseases, University of Rome La Sapienza</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Biosciences and Territory, University of Molise</institution>, <addr-line>Pesche</addr-line>, <country>Italy</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Gynecological-Obstetric and Urological Sciences, University of Rome La Sapienza</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by"><p><text><SENT sid="1" pm="."><plain>Edited by: Olivier Garraud, Institut National de la Transfusion Sanguine, France </plain></SENT>
</text></p></fn><fn fn-type="edited-by"><p><text><SENT sid="2" pm="."><plain>Reviewed by: Salvatore Giovanni Vitale, Università degli Studi di Messina, Italy; Eva-Maria Hanschmann, Heinrich Heine Universität Düsseldorf, Germany </plain></SENT>
</text></p></fn><corresp id="c001">*Correspondence: Piera Valenti <email>piera.valenti@uniroma1.it</email></corresp><fn fn-type="other" id="fn001"><p><text><SENT sid="3" pm="."><plain>This article was submitted to Inflammation, a section of the journal Frontiers in Immunology </plain></SENT>
</text></p></fn><fn fn-type="other" id="fn002"><p><text><SENT sid="4" pm="."><plain>†These authors have contributed equally to this work </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>2123</elocation-id><history><date date-type="received"><day>31</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 Lepanto, Rosa, Cutone, Conte, Paesano and Valenti.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Lepanto, Rosa, Cutone, Conte, Paesano and Valenti</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>The discovery of the ferroportin-hepcidin complex has led to a critical review on the treatment of anemia and anemia of inflammation (AI). </plain></SENT>
<SENT sid="6" pm="."><plain>Ferroportin, the only known mammalian iron exporter from cells to blood, is negatively regulated by hepcidin, a hormone peptide able to bind to ferroportin, leading to its degradation. </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, new efficient therapeutic interventions acting on hepcidin and ferroportin are imperative to manage anemia and AI. </plain></SENT>
<SENT sid="8" pm="."><plain>Bovine milk derivative lactoferrin (bLf), a glycoprotein able to chelate two ferric ions per molecule, is emerging as a natural anti-inflammatory substance able to modulate hepcidin and ferroportin synthesis through the down-regulation of interleukin-6 (IL-6). </plain></SENT>
<SENT sid="9" pm="."><plain>Here, an interventional study (ClinicalTrials.gov Identifier: NCT01221844) was conducted by orally administering 100 mg of 20–30% iron-saturated bLf (corresponding to 70–84 μg of elemental iron) twice a day. </plain></SENT>
<SENT sid="10" pm="."><plain>This treatment was compared with the Italian standard therapy, consisting in the oral administration of 329.7 mg of ferrous sulfate once a day (corresponding to 105 mg of elemental iron). </plain></SENT>
<SENT sid="11" pm="."><plain>Treatments were carried out on 29 anemic women with minor β-thalassemia (20 pregnant and 9 non-pregnant), 149 women with hereditary thrombophilia (HT) (70 pregnant and 79 non-pregnant) affected by AI and 20 anemic pregnant women suffering from various pathologies. </plain></SENT>
<SENT sid="12" pm="."><plain>In anemic pregnant and non-pregnant women with minor β-thalassemia, presenting undetectable hepcidin levels, differently from ferrous sulfate management, bLf decreased IL-6 (from 25 ± 8 to 6 ± 3 pg/ml) and increased total serum iron (TSI) (from 54 ± 17 to 80 ± 9 μg/dl). </plain></SENT>
<SENT sid="13" pm="."><plain>BLf was also more efficient than ferrous sulfate in AI treatment in HT pregnant and non-pregnant women by decreasing both serum IL-6 (from 89 ± 8 to 58 ± 6 pg/ml) and hepcidin (from 115 ± 23 to 65 ± 10 ng/ml), thus increasing hematological parameters, such as the number of red blood cells (RBCs), the concentration of hemoglobin, TSI and serum ferritin. </plain></SENT>
<SENT sid="14" pm="."><plain>BLf was also efficient in treating anemia in other pathological pregnancies. </plain></SENT>
<SENT sid="15" pm="."><plain>Taken together all the results, bLf, showing a greater benefit and efficacy than the standard ferrous sulfate management, can be considered as a promising compound in treating anemia and AI through its ability to down-regulate IL-6, thus restoring ferroportin-mediated iron export from cells to blood in a hepcidin-dependent or independent way. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>lactoferrin</kwd><kwd>iron</kwd><kwd>anemia</kwd><kwd>anemia of inflammation</kwd><kwd>β-thalassemia</kwd><kwd>hereditary thrombophilia</kwd></kwd-group></SecTag><counts><fig-count count="1"/><table-count count="10"/><equation-count count="0"/><ref-count count="51"/><page-count count="12"/><word-count count="9112"/></counts></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s1"><title><text><SENT sid="16" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain>Iron is an essential nutrient for living cells and it is pivotal during pregnancy, in particular for the developing fetus through maternal iron transfer as well as in the neonate through breast-feeding and in the childhood through diet. </plain></SENT>
<SENT sid="18" pm="."><plain>Iron deficiency (ID) is considered the most important nutritional disorder in the world, being more prevalent in pregnant women where represents a high risk factor for maternal and infant health associated with preterm delivery, fetal growth retardation, low birth weight, and inferior neonatal health (1). </plain></SENT>
<SENT sid="19" pm="."><plain>ID is also frequent in children where is related to decreased brain functions (2, 3). </plain></SENT>
<SENT sid="20" pm="."><plain>Moreover, women of reproductive age can be affected by ID due to iron loss during the menses. </plain></SENT>
<SENT sid="21" pm="."><plain>An early diagnosis and a prompt management of ID and ID anemia (IDA) are highly recommended. </plain></SENT>
<SENT sid="22" pm="."><plain>ID is characterized by the low levels of total serum iron (TSI) and serum ferritin (sFtn). </plain></SENT>
<SENT sid="23" pm="."><plain>Conversely, IDA is characterized by low concentrations of hemoglobin (Hb) and low number of red blood cells (RBCs) in addition to TSI and sFtn low levels. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>The human body contains 3–4 g of iron localized in hemoglobin of erythrocytes (about 2.0–2.5 g), in ferritin (Ftn) within hepatocytes and macrophages (about 0.5–1 g), in myoglobin, and in iron-containing enzymes (about 0.5 g). </plain></SENT>
<SENT sid="25" pm="."><plain>A minor iron source, deriving from an equilibrated diet, provides about 15 mg of iron per day of which only about 10%, corresponding to 1–2 mg, is absorbed due to its exceptionally poor bio-availability. </plain></SENT>
<SENT sid="26" pm="."><plain>A major iron source involves the recycling of iron from the lysis of senescent erythrocytes by macrophages (about 20 mg/day) (4, 5). </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>The correct balance of iron between tissues/secretions and blood, defined iron homeostasis, is regulated by two main factors, ferroportin (Fpn) and hepcidin (6, 7). </plain></SENT>
<SENT sid="28" pm="."><plain>Fpn is the only known mammalian iron exporter from tissues to blood (6) down-regulated by the pro-inflammatory interleukin (IL)-6 (8, 9). </plain></SENT>
<SENT sid="29" pm="."><plain>Hepcidin, a 25 amino acids cationic peptide hormone, identified in plasma (6) and urine (10, 11), is modulated by iron stores and it is up-regulated by pro-inflammatory cytokines, such as IL-6, IL-1α, and IL-1β (12–16). </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>Overall, iron homeostasis is highly regulated through three different pathways: iron absorption in apical side of enterocytes, iron storage into ferritin and iron export by Fpn (17, 18). </plain></SENT>
<SENT sid="31" pm="."><plain>Fpn, besides IL-6 and the amount of intracellular iron/heme, is regulated also by hepcidin which is able to bind to Fpn, leading to its internalization and degradation (19). </plain></SENT>
<SENT sid="32" pm="."><plain>Consequently, high hepcidin concentrations inhibit iron export from cells to blood while low levels allow iron export through Fpn (5, 20). </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>Interestingly, in the recent study by Willemetz et al. (21), it has been demonstrated, in a model of hepcidin knockout (Hamp−/−) murine macrophages infected by Salmonella enterica, that Fpn down-regulation can occur also in a hepcidin-independent manner (21). </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>The iron homeostasis disorders consist in the up-expression of hepcidin and the subsequent down-regulation of Fpn leading to anemia of inflammation (AI), a pathological condition characterized by low hematological parameters, normal-to-elevated sFtn, high levels of IL-6 and of other pro-inflammatory cytokines (22). </plain></SENT>
<SENT sid="35" pm="."><plain>These disorders are traditionally treated with iron supplementations. </plain></SENT>
<SENT sid="36" pm="."><plain>However, in papers by Paesano et al. (4) and Rosa et al. (23) the iron homeostasis disorders have not been defined as iron deficiency but as iron delocalization, characterized by iron overload in tissues/secretions and iron deficiency in blood. </plain></SENT>
<SENT sid="37" pm="."><plain>In a pathological condition occurring in patients affected by β-thalassemia, one of the types of thalassemia caused by a mutation in the β-globin gene (HBB) on chromosome 11, hepcidin production is suppressed (5, 20). </plain></SENT>
<SENT sid="38" pm="."><plain>The phenotypes of β-thalassemias include β-thalassemia major, intermedia and minor, according to the severity of the genetic mutation. </plain></SENT>
<SENT sid="39" pm="."><plain>Individuals with β-thalassemia major, characterized by marked ineffective erythropoiesis and severe hemolysis, as well as with β-thalassemia intermedia, characterized by widely variable symptoms and severity ranging between the two extremes of the major and minor forms, require frequent to occasional RBCs transfusions to sustain life (24–26). </plain></SENT>
<SENT sid="40" pm="."><plain>Among β-thalassemic (27, 28), the subjects affected by minor β-thalassemia, clinically asymptomatic and characterized by morphological abnormalities of erythrocytes as well as by a slight lowering of the hemoglobin levels, show the disorders of iron homeostasis sometimes leading to a mild anemia (24). </plain></SENT>
<SENT sid="41" pm="."><plain>During pregnancy, despite the progress of therapies, maternal and fetal complications, such as risk of abortion, thromboembolism, pre-term delivery and intrauterine growth restriction, appear to be increased in patients with β-thalassemia major, occurring in almost 40% of pregnancies, as well as in patients with β-thalassemia intermedia, occurring in 20–30% of pregnancies, compared to healthy ones (25, 26). </plain></SENT>
<SENT sid="42" pm="."><plain>Regarding β-thalassemia minor, the incidence of premature and low birth weight infants was found to be comparable to the general population. </plain></SENT>
<SENT sid="43" pm="."><plain>Of note, there is no specific therapy for β-thalassemia minor subjects during pregnancy, but if the anemia becomes more severe transfusions are sometimes necessary (25, 26). </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>Concerning the other pathology treated in this study, the hereditary thrombophilia (HT), there are no data in literature on the correlation between hepcidin levels and the establishing of AI in HT subjects. </plain></SENT>
<SENT sid="45" pm="."><plain>However, higher levels of serum IL-6 compared to healthy subjects have been described in HT pregnant women (29). </plain></SENT>
<SENT sid="46" pm="."><plain>HT is a genetic predisposition to the formation of venous thrombus due to coagulation abnormalities (30, 31). </plain></SENT>
<SENT sid="47" pm="."><plain>During pregnancy, this hypercoagulable state is exacerbated due to the increase of factors VII, VIII, X and von Willebrand factor activities and to marked increases in fibrinogen (32). </plain></SENT>
<SENT sid="48" pm="."><plain>Thrombin generation markers such as prothrombin F1 and F2 also increase (33). </plain></SENT>
<SENT sid="49" pm="."><plain>Moreover, activation of the coagulation system is characterized by the co-participation of inflammatory response components as IL-6, IL-8, and TNF-α (34). </plain></SENT>
<SENT sid="50" pm="."><plain>All these changes can predispose to several maternal and fetal complications during the pregnancy, including pre-eclampsia, late and recurrent early miscarriage, placental abruption, fetal growth restriction (FGR), and intrauterine death and stillbirth (33). </plain></SENT>
<SENT sid="51" pm="."><plain>For all these reasons, in order to avoid maternal and fetal sequelae, all HT pregnant women must undergo a proper therapeutic management. </plain></SENT>
</text></p><p><text><SENT sid="52" pm="."><plain>An important component of iron and inflammatory homeostasis machinery is an iron binding glycoprotein, named lactoferrin (Lf), present in human secretions, like milk, saliva, vaginal fluid, amniotic fluid, upper airway fluid, seminal plasma, the cervical mucus, and earwax (23). </plain></SENT>
<SENT sid="53" pm="."><plain>Similar to proteins of the secretions, Lf is a multifunctional glycoprotein able to protect mucosa from the injury of microbial attachment and colonization as well as to exert anti-inflammatory activity (18, 35). </plain></SENT>
<SENT sid="54" pm="."><plain>The bovine milk derivative lactoferrin (bLf), generally recognized as safe (GRAS) by Food and Drug Administration (FDA-USA), is emerging as an important natural glycoprotein able to treat IDA and AI (4, 29, 36–38). </plain></SENT>
<SENT sid="55" pm="."><plain>The efficacy of bLf treatment is related to its ability to decrease IL-6 concentration which, in turn, modulates hepcidin and Fpn synthesis. </plain></SENT>
<SENT sid="56" pm="."><plain>Recent in vitro studies showed how high levels of IL-6 down-regulate the expression of Fpn in inflamed-macrophages and how bLf is able to efficiently revert this effect, down-regulating IL-6 and up-regulating Fpn (8, 9). </plain></SENT>
<SENT sid="57" pm="."><plain>These results demonstrate that bLf, able to decrease IL-6 levels, exerts a role in iron and inflammatory homeostasis and, especially, in treating AI. </plain></SENT>
</text></p><p><text><SENT sid="58" pm="."><plain>Of note, previous in vivo studies have reported non-pregnant women affected by minor β-thalassemia to possess higher levels of IL-6 compared with non-pregnant healthy women (38). </plain></SENT>
<SENT sid="59" pm="."><plain>Conversely, pregnant women suffering of minor β-thalassemia have been found to possess higher, but not-significant, levels of IL-6 compared with healthy pregnancies (38). </plain></SENT>
<SENT sid="60" pm="."><plain>Regarding HT pregnant and non-pregnant women, they have been described with higher levels of IL-6 compared with healthy pregnancies (29, 38). </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>Here, we present the data on the efficacy of bLf oral administration in treating anemia in minor β-thalassemic pregnant and non-pregnant women as well as in the management of AI in pregnant and non-pregnant women affected by HT. </plain></SENT>
<SENT sid="62" pm="."><plain>The bLf efficacy is also reported in pregnant women suffering from other pathologies. </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>Remarkably, for the first time, we demonstrate that the efficacy of bLf in treating anemia and AI in β-thalassemic and HT women, respectively, can be correlated, in addition to the decrease to the IL-6, with two potential different molecular mechanisms: hepcidin-independent for β-thalassemic and hepcidin-dependent for HT women. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials and methods" id="s2"><title><text><SENT sid="64" pm="."><plain>Materials and methods </plain></SENT>
</text></title><sec><title><text><SENT sid="65" pm="."><plain>Study design </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>To compare the efficacy of bLf treatment vs. the Italian ferrous sulfate one, usually applied worldwide as standard treatment, in the management of anemia and AI in pregnant and non-pregnant women affected by minor β-thalassemia and HT, respectively, a monocentric interventional clinical study has been conducted. </plain></SENT>
<SENT sid="67" pm="."><plain>In addition, the efficacy of bLf oral administration was also carried out on anemic pregnant women suffering from different pathologies as epilepsy, insulin resistance diabetes type 2, Crohn's disease, hypertension and HT (twin pregnancies). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="68" pm="."><plain>Setting </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>The interventional clinical study (ClinicalTrials.gov Identifier: NCT01221844) has been conducted at Clinica Fabia Mater, via Olevano Romano 25, Rome, Italy, a secondary-level hospital for complicated pregnancies, in accordance with the ethical principles of the Declaration of Helsinki and the Good Clinical Practice. </plain></SENT>
<SENT sid="70" pm="."><plain>Approval was granted by the Ethics Committee of Clinica Fabia Mater, via Olevano Romano 25, Rome, Italy (FM MOD 26022010). </plain></SENT>
<SENT sid="71" pm="."><plain>All women gave written informed consent before undergoing any study procedure. </plain></SENT>
<SENT sid="72" pm="."><plain>All women have been recruited from June 2010 to October 2013. </plain></SENT>
<SENT sid="73" pm="."><plain>All pregnant women were examined at the time of enrolment and every 30 days at the scheduled visits until delivery. </plain></SENT>
<SENT sid="74" pm="."><plain>All women of child-bearing age were examined at the time of enrolment and 30 days after treatments. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="75" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="76" pm="."><plain>A total of 90 anemic pregnant women between the 6th and 8th week of gestation has been enrolled, thereof 20 women with minor β-thalassemia and 70 with HT, and 20 anemic affected by other pathologies, including epilepsy (No 9), insulin resistance diabetes type 2 (No 3), Crohn's disease (No 3), hypertension (No 2), and HT twin pregnancies (No 3), enrolled at different weeks of gestation. </plain></SENT>
</text></p><p><text><SENT sid="77" pm="."><plain>Pregnant women with uncomplicated pregnancy were excluded as well as if smokers or if they had anti-phospholipid syndrome, other concomitant diseases, infections, previous iron supplementation therapy, recent blood transfusion(s), obesity, and allergy to milk proteins, factors that could be considered potential modifiers of the treatments. </plain></SENT>
<SENT sid="78" pm="."><plain>In addition, this interventional clinical study included 88 anemic women of child-bearing age, thereof 9 affected by minor β-thalassemia and 79 by HT. </plain></SENT>
</text></p><p><text><SENT sid="79" pm="."><plain>Non-pregnant women were excluded if smokers or if they had other concomitant diseases, infections, previous iron supplementation therapy, recent blood transfusion(s), obesity and allergy to milk proteins. </plain></SENT>
</text></p><p><text><SENT sid="80" pm="."><plain>All enrolled HT pregnant and non-pregnant women received low molecular-weight heparin (0.3 U/day of Seleparina, Italfarmaco SpA, Milano-Italy) and low dose aspirin (100 mg every 2 days of Cardioaspirin® 100, Bayer SpA, Milano-Italy) to prevent and reduce the risk of venous thromboembolism and miscarriage associated to hypercoagulability (39). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="81" pm="."><plain>Blood analyses </plain></SENT>
</text></title><p><text><SENT sid="82" pm="."><plain>Each blood sample was harvested, aliquoted, and stored at −80°C in order to analyze the parameters at different times. </plain></SENT>
<SENT sid="83" pm="."><plain>The anemia is defined when one of the hematological parameters corresponded to the following values: RBCs &lt;4,000,000/ml, Hb &lt;11 g/dl, TSI &lt;30 μg/dl, and sFtn &lt;12 ng/ml. </plain></SENT>
</text></p><p><text><SENT sid="84" pm="."><plain>The diagnosis of β-thalassemia was carried out, at the laboratory of Clinica Fabia Mater, by the analysis of the hematological parameters including red cell morphology and indices that revealed microcytosis (low mean corpuscular volume, MCV), reduced content of Hb per red cell (low mean corpuscular hemoglobin, MCH), followed by separation and measurement of Hb fractions through electrophoresis (40). </plain></SENT>
</text></p><p><text><SENT sid="85" pm="."><plain>Moreover, TSI and sFtn were assessed from venous blood. </plain></SENT>
<SENT sid="86" pm="."><plain>In particular, TSI was measured using an Iron FZ assay (Hoffmann-LaRoche, Basel, Switzerland) based on a guanidine hydrochloride/Ferrozine reaction, while sFtn was measured using a radioimmunoassay (Spectria, Orion Diagnostics). </plain></SENT>
<SENT sid="87" pm="."><plain>Serum IL-6 and hepcidin were also detected. </plain></SENT>
<SENT sid="88" pm="."><plain>Serum IL-6 levels were determined by standard ELISA Quantitative kits (R&amp;D Systems, Wiesbaden, Germany) at Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, on the samples collected before and after treatment. </plain></SENT>
<SENT sid="89" pm="."><plain>Serum hepcidin was detected according to competitive enzyme-linked immunosorbent assay (Intrinsic Life Sciences, La Jolla, CA) at Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy. </plain></SENT>
</text></p><p><text><SENT sid="90" pm="."><plain>The diagnosis of HT was performed at Institute Regina Elena, Department of Medical Pathology, Rome, Italy according to Jackson et al. (41). </plain></SENT>
<SENT sid="91" pm="."><plain>In particular, pregnant women with a history of adverse outcomes including recurrent miscarriages, preterm birth, intrauterine growth restriction, were screened for the following HT markers before the enrolment: protein C, protein S, activated protein C resistance, antithrombin deficiencies, elevated coagulation factors, hyperhomocysteinemia, F5 R506Q (factor V Leiden) and F2 G20210A (prothrombin G20210A) mutations. </plain></SENT>
<SENT sid="92" pm="."><plain>When at least one of these HT markers was found, pregnant women were considered affected by HT. </plain></SENT>
<SENT sid="93" pm="."><plain>All HT women were further screened for hematological parameters as RBCs, Hb, TSI, and sFtn as well as for serum IL-6 and serum hepcidin before starting and after 30 days of the treatments. </plain></SENT>
</text></p><p><text><SENT sid="94" pm="."><plain>Moreover, for all enrolled women, the values of hematocrit, glycemia, uricemia, bilirubin, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, cholesterol, triglyceride acid, and electrolytes were evaluated at each visit (data not shown). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="95" pm="."><plain>Clinical examination </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>To evaluate the putative adverse effects of the treatments in pregnant women, the main outcomes were based on the estimation of maternal gastrointestinal discomfort, nausea, vomiting, diarrhea, and constipation. </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>At each visit, fetal vital sign assessments were monitored by ultrasonographic measurements of intrauterine growth and through the amount of amniotic fluid, expressed as amniotic fluid index (AFI), an index for the fetal well-being (42). </plain></SENT>
<SENT sid="98" pm="."><plain>An AFI of ≤5 cm was considered oligohydramnios, 5–8 cm borderline, and from 8 to 24 cm normal (42). </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>At the delivery, new-born weight and the APGAR score were also registered. </plain></SENT>
<SENT sid="100" pm="."><plain>The APGAR score is a practical method to evaluate the physical condition of a new-born shortly after delivery. </plain></SENT>
<SENT sid="101" pm="."><plain>The Apgar score comprises five components: (1) color, (2) heart rate, (3) reflexes, (4) muscle tone, and (5) respiration, each of which is given a score of 0, 1, or 2. </plain></SENT>
<SENT sid="102" pm="."><plain>An APGAR score of 0–3 at 5–10 min of age is predictive of high morbidity and mortality, a score of 4–6 as moderately abnormal, while a value of 9–10 indicates that the infant is in the best possible condition. </plain></SENT>
</text></p><p><text><SENT sid="103" pm="."><plain>The adverse effects in women of child-bearing age were evaluated by gastrointestinal discomfort, nausea, vomiting, diarrhea and constipation. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="104" pm="."><plain>Interventions </plain></SENT>
</text></title><p><text><SENT sid="105" pm="."><plain>Pregnant and child-bearing age women affected by minor β-thalassemia and HT suffering from anemia and AI, respectively, were assigned to different Arms on the basis of a personal preference. </plain></SENT>
<SENT sid="106" pm="."><plain>As matter of fact, before starting the study patients choose by themselves which treatment to adhere to. </plain></SENT>
</text></p><p><text><SENT sid="107" pm="."><plain>Women included in Arm A, C, E, and G received the treatment based on the oral administration of one capsule containing 100 mg of bLf plus excipients (Lattoglobina®, Italy) two times a day before meals, to avoid the protein degradation due to the low pH of gastric juice during digestion (about 1.5). </plain></SENT>
<SENT sid="108" pm="."><plain>Conversely, at pH about 4, characteristic of gastric juice before meals, 90% of the administered bLf arrives undigested to the intestine (43). </plain></SENT>
<SENT sid="109" pm="."><plain>The total amount of elemental iron supplied by Lattoglobina® capsules corresponded to about 70–84 μg/day, depending on the degree of iron saturation (20–30%). </plain></SENT>
<SENT sid="110" pm="."><plain>Women included in Arm B, D, F, and H received the standard treatment based on the oral administration of a tablet containing 329.7 mg of ferrous sulfate (Ferro-Grad®, Abbot Laboratories, USA) once a day during meal, in order to avoid a possible gastric intolerance of the drug, according to the Italian Standard of Care. </plain></SENT>
<SENT sid="111" pm="."><plain>The total amount of elemental iron supplied by Ferro-Grad® tablets corresponded to about 105 mg/day. </plain></SENT>
</text></p><p><text><SENT sid="112" pm="."><plain>All pregnant women affected by different pathologies, previously described, received oral administration of one capsule containing 100 mg of bLf plus excipients (Lattoglobina®, Italy) twice a day before meals, while HT women with twin pregnancies three times a day, more efficient in increasing hematological parameters than the administration of bLf twice a day. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="113" pm="."><plain>Further laboratory analysis </plain></SENT>
</text></title><p><text><SENT sid="114" pm="."><plain>The purity of the encapsulated bLf (Molecular Weight of about 80 kDa) was checked by SDS-PAGE and silver nitrate staining, while its concentration was assessed by UV spectroscopy on the basis of an extinction coefficient of 15.1 (280 nm, 1% solution). </plain></SENT>
<SENT sid="115" pm="."><plain>The bLf iron saturation was about 20–30% as detected by optical spectroscopy at 468 nm on the basis of an extinction coefficient of 0.54 (100% iron saturation, 1% solution). </plain></SENT>
<SENT sid="116" pm="."><plain>The total amount of elemental iron supplied by Lattoglobina® capsules corresponded to about 70–84 μg/day, depending on the degree of iron saturation (20–30%). </plain></SENT>
<SENT sid="117" pm="."><plain>LPS contamination of bLf, estimated by Limulus Amebocyte assay (Pyrochrome kit, PBI International), was equal to 0.7 ± 0.06 ng/mg of bLf (9, 43). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="118" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="119" pm="."><plain>Statistical analysis was carried out using the ANOVA test. P-values has been obtained comparing before and after 30 days of each treatment the number of RBCs, the concentration of Hb, TSI, sFtn, IL-6 and hepcidin. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s3"><title><text><SENT sid="120" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="121" pm="."><plain>Demographics </plain></SENT>
</text></title><p><text><SENT sid="122" pm="."><plain>A total of 20 minor β-thalassemic and 70 HT pregnant women suffering from anemia and AI, respectively, was enrolled in the interventional clinical trial within the first trimester of pregnancy (Figures 1A,B). </plain></SENT>
<SENT sid="123" pm="."><plain>On the basis of their personal preference, 12 and 8 minor β-thalassemic pregnant women were included in Arm A (bLf intervention) and Arm B (ferrous sulfate intervention), respectively (Figure 1A). </plain></SENT>
<SENT sid="124" pm="."><plain>Among 8 minor β-thalassemic pregnant women belonging to Arm B, 2 withdrew the study for adverse effects (diarrhea) (Figure 1A). </plain></SENT>
<SENT sid="125" pm="."><plain>Regarding HT pregnant women, on the basis of their personal preference, 40 were included in Arm C (bLf intervention) and 30 in Arm D (ferrous sulfate intervention) (Figure 1B). </plain></SENT>
<SENT sid="126" pm="."><plain>Among 30 HT pregnant women belonging to Arm D, 5 withdrew the study for adverse effects: 2 for gastrointestinal discomfort and 3 for diarrhea (Figure 1B). </plain></SENT>
<SENT sid="127" pm="."><plain>Demographics and hematological parameters of minor β-thalassemic and HT pregnant women, who completed the study, are reported in Table 1. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="128" pm="."><plain>Flow diagrams of enrolled pregnant women suffering from minor β-thalassemia (A), pregnant women suffering from hereditary thrombophilia (B), women of child-bearing age suffering from minor β-thalassemia (C), women of child-bearing age suffering from hereditary thrombophilia (D). </plain></SENT>
</text></p></caption><graphic xlink:href="fimmu-09-02123-g0001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="129" pm="."><plain>Demographics and baseline of hematological mean values ± SD of minor β-thalassemic and HT pregnant women affected by anemia and AI, respectively, enrolled between the 6th and 8th week of gestation. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>Minor β-thalassemic pregnant women </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>HT pregnant women </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>No of pregnant women completing the study </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>18 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>65 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>Age (year) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>28 ± 3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>34 ± 3 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>Red blood cells x103 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>4, 470±184 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>3, 700±145 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>Hemoglobin (g/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>7.7 ± 1.4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>10.7 ± 0.6 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>Total serum iron (μg/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>50 ± 14 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>38 ± 13 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>Serum ferritin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>24 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>14 ± 10 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>Serum IL-6 (pg/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>29 ± 9 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>87 ± 10 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Hepcidin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>111 ± 26 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="156" pm="."><plain>Moreover, 20 anemic pregnant women suffering from other pathologies, including epilepsy (No 9), insulin resistance diabetes type 2 (No 3), Crohn's disease (No 3), hypertension (No 2) and HT with twin pregnancies (No 3), have been enrolled at different trimesters of pregnancy and exclusively treated with bLf oral administration. </plain></SENT>
<SENT sid="157" pm="."><plain>Demographics as well as Hb and TSI values are reported in Table 2. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><text><SENT sid="158" pm="."><plain>Demographics and baseline of hemoglobin and total serum iron mean values ± SD of pathological pregnancies affected by anemia enrolled at different trimesters of gestation. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>No of women </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Pathology </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>Age (year) </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>Week of pregnancy </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>Hb (g/dl) </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>TSI (μg/dl) </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>9 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>Epilepsy </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>33 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>17 ± 6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>11.1 ± 0.6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>42 ± 16 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>Insulin resistance diabetes type 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>35 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>28 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>10.4 ± 0.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>33 ± 2 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>Crohn's disease </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>31 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>29 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>9.4 ± 1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>57 ± 7 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>2 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>Hypertension </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>34 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>24 ± 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>10.7 ± 0.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>35 ± 5 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>HT (twin) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>33 ± 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>25 ± 8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>10.5 ± 0.5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>47 ± 14 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="195" pm="."><plain>Hb, hemoglobin; TSI, total serum iron. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="196" pm="."><plain>A total of 9 minor β-thalassemic and 79 HT women of child-bearing age suffering from anemia and AI, respectively, was also enrolled. </plain></SENT>
<SENT sid="197" pm="."><plain>On the basis of their personal preference, 9 minor β-thalassemic women of child-bearing age were divided in Arm E (No 5, bLf intervention) and Arm F (No 4, ferrous sulfate intervention), respectively, and completed the study (Figure 1C). </plain></SENT>
<SENT sid="198" pm="."><plain>Regarding HT women of child-bearing age, on the basis of their personal preference, 41 were included in Arm G (bLf intervention) and 38 in Arm H (ferrous sulfate intervention) (Figure 1D). </plain></SENT>
<SENT sid="199" pm="."><plain>Among 38 HT women belonging to Arm H, 2 withdrew the study for nausea and vomiting and 4 for diarrhea (Figure 1D). </plain></SENT>
</text></p><p><text><SENT sid="200" pm="."><plain>Demographics and hematological parameters of enrolled women of child-bearing age are summarized in Table 3. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><text><SENT sid="201" pm="."><plain>Demographics and baseline hematological mean values ± SD of minor β-thalassemic and HT women of child-bearing age affected by anemia and AI, respectively. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>Minor β-thalassemic women </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>HT women </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>No of women completing the study </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>9 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>73 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>Age (year) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>32 ± 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>31 ± 3 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>Red blood cells × 103 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>4, 287±497 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>3, 876±247 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>Hemoglobin (g/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>10.6 ± 1.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>10.9 ± 0.8 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>Total serum iron (μg/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>41 ± 11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>38 ± 11 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>Serum ferritin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>15 ± 5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>10 ± 4 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>Serum IL-6 (pg/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>25 ± 13 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>43 ± 11 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>Hepcidin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>102 ± 9 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></sec><sec><title><text><SENT sid="228" pm="."><plain>Efficacy of bovine lactoferrin vs. ferrous sulfate treatment in pregnancy against anemia and AI </plain></SENT>
</text></title><p><text><SENT sid="229" pm="."><plain>In pregnant women suffering from minor β-thalassemia and HT, the RBCs, Hb, TSI, sFtn, serum IL-6, and hepcidin were assessed before and every 30 days of treatments until delivery. </plain></SENT>
<SENT sid="230" pm="."><plain>The results obtained after the first 30 days of both interventions and at delivery, independently from the week of the gestation, are presented in the Tables 4, 5 for minor β-thalassemic and in Tables 6, 7 for HT pregnant women, respectively. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T4" position="float"><label>Table 4</label><caption><p><text><SENT sid="231" pm="."><plain>Hematological parameters, serum IL-6 and hepcidin mean values ± SD of anemic minor β-thalassemic pregnant women treated with bovine lactoferrin (Arm A) or ferrous sulfate (Arm B), before and after 30 days of treatment. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="4" rowspan="1"><text><SENT sid="232" pm="."><plain>Minor β-thalassemic pregnant women </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="233" pm="."><plain>Arm A </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="234" pm="."><plain>Arm B </plain></SENT>
</text></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>No of pregnant women completing the study Treatment </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="236" pm="."><plain>12 </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="237" pm="."><plain>6 </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="238" pm="."><plain>Bovine lactoferrin </plain></SENT>
</text></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="239" pm="."><plain>Ferrous sulfate </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>After 30 days </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>After 30 days </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>Red blood cells × 103 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>4, 487±167 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>4, 460±121 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>4, 453±201 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>4, 130±123 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Hemoglobin (g/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>7.8 ± 1.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>11.7 ± 0.8* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>7.6 ± 1.6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>10.2 ± 0.9* </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>Total serum iron (μg/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>54 ± 17 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>80 ± 9 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>46 ± 11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>50 ± 12 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>Serum ferritin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>23 ± 5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>28 ± 3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>25 ± 3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>24 ± 4 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>Serum IL-6 (pg/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>25 ± 8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>6 ± 3* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>33 ± 10 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>36 ± 8 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>Hepcidin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="TN1"><label>*</label><p><text><SENT sid="274" pm="."><plain>Significantly different from before treatment (p &lt; 0.001). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T5" position="float"><label>Table 5</label><caption><p><text><SENT sid="275" pm="."><plain>Hematological parameters, serum IL-6 and hepcidin mean values ± SD of anemic minor β-thalassemic pregnant women treated with bovine lactoferrin (Arm A) or ferrous sulfate (Arm B), before the treatment and at delivery. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="4" rowspan="1"><text><SENT sid="276" pm="."><plain>Minor β-thalassemic pregnant women </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="277" pm="."><plain>Arm A </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="278" pm="."><plain>Arm B </plain></SENT>
</text></th></tr><tr><th valign="top" style="border-bottom: thin solid #000000;" align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>No of pregnant women completing the study Treatment </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="280" pm="."><plain>12 </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="281" pm="."><plain>6 </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="282" pm="."><plain>Bovine lactoferrin </plain></SENT>
</text></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="283" pm="."><plain>Ferrous sulfate </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>At delivery </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>At delivery </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>Red blood cells × 103 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>4, 487±167 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>4, 610±196 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>4, 453±201 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>4, 284±183 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>Hemoglobin (g/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>7.8 ± 1.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>11.9 ± 0.7* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>7.6 ± 1.6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>10.8 ± 0.6* </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>Total serum iron (μg/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>54 ± 17 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>87 ± 16 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>46 ± 11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>55 ± 17 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>Serum ferritin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>23 ± 5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>34 ± 6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>25 ± 3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>21 ± 7 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>Serum IL-6 (pg/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>25 ± 8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>5 ± 4* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>33 ± 10 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>34 ± 10 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>Hepcidin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="TN2"><label>*</label><p><text><SENT sid="318" pm="."><plain>Significantly different from before treatment (p &lt; 0.001). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T6" position="float"><label>Table 6</label><caption><p><text><SENT sid="319" pm="."><plain>Hematological parameters, serum IL-6 and hepcidin mean values ± SD of HT pregnant women, suffering from AI, treated with bovine lactoferrin (Arm C) or with ferrous sulfate (Arm D), before and after 30 days of treatment. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="4" rowspan="1"><text><SENT sid="320" pm="."><plain>HT pregnant women </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="321" pm="."><plain>Arm C </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="322" pm="."><plain>Arm D </plain></SENT>
</text></th></tr><tr><th valign="top" style="border-bottom: thin solid #000000;" align="left" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>No of pregnant women completing the study Treatment </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="324" pm="."><plain>40 </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="325" pm="."><plain>25 </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="326" pm="."><plain>Bovine lactoferrin </plain></SENT>
</text></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="327" pm="."><plain>Ferrous sulfate </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>After 30 days </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>After 30 days </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>Red blood cells × 103 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>3, 750±127 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>4, 354±198* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>3, 650±163 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>3, 960±230 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>Hemoglobin (g/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>10.6 ± 0.4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>12.2 ± 0.4* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>10.8 ± 0.8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>11.3 ± 1.1 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>Total serum iron (μg/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>36 ± 11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>63 ± 9* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>40 ± 15 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>40 ± 6 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>Serum ferritin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>11 ± 6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>18 ± 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>17 ± 14 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>14 ± 9 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>Serum IL-6 (pg/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>89 ± 8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>58 ± 6* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>85 ± 12 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>108 ± 7 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>Hepcidin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>115 ± 23 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>65 ± 10* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>107 ± 29 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>112 ± 32 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="TN3"><label>*</label><p><text><SENT sid="362" pm="."><plain>Significantly different from before treatment (p &lt; 0.001). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T7" position="float"><label>Table 7</label><caption><p><text><SENT sid="363" pm="."><plain>Hematological parameters, serum IL-6 and hepcidin mean values ± SD of HT pregnant women, suffering from AI, treated with bovine lactoferrin (Arm C) or with ferrous sulfate (Arm D), before the treatment and at delivery. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="4" rowspan="1"><text><SENT sid="364" pm="."><plain>HT pregnant women </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="365" pm="."><plain>Arm C </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="366" pm="."><plain>Arm D </plain></SENT>
</text></th></tr><tr><th valign="top" style="border-bottom: thin solid #000000;" align="left" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>No of pregnant women completing the study Treatment </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="368" pm="."><plain>40 </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="369" pm="."><plain>25 </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="370" pm="."><plain>Bovine lactoferrin </plain></SENT>
</text></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="371" pm="."><plain>Ferrous sulfate </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>At delivery </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>At delivery </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>Red blood cells × 103 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>3, 750±127 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>4, 482±147* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>3, 650±163 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>4, 029±287 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>Hemoglobin (g/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>10.6 ± 0.4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>12.7 ± 0.5* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>10.8 ± 0.8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>11.2 ± 0.9 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>Total serum iron (μg/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>36 ± 11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>85 ± 10* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>40 ± 15 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>38 ± 11 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>Serum ferritin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>11 ± 6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>31 ± 3* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>17 ± 14 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>12 ± 10 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>Serum IL-6 (pg/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>89 ± 8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>50 ± 5* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>85 ± 12 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>113 ± 15 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>Hepcidin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>115 ± 23 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>54 ± 13* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>107 ± 29 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>116 ± 26 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="TN4"><label>*</label><p><text><SENT sid="406" pm="."><plain>Significantly different from before treatment (p &lt; 0.001). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="407" pm="."><plain>As shown in Table 4, minor β-thalassemic pregnant women treated for 30 days with bLf (Arm A) showed a significant increase of Hb (from 7.8 ± 1.3 to 11.7 ± 0.8 g/dl) as well as a signficant decrease of IL-6 (from 25 ± 8 to 6 ± 3 pg/ml). </plain></SENT>
<SENT sid="408" pm="."><plain>Of note, a remarkable increase of TSI (from 54 ± 17 to 80 ± 9 μg/dl) was also observed. </plain></SENT>
<SENT sid="409" pm="."><plain>Conversely, minor β-thalassemic pregnant women treated for 30 days with ferrous sulfate (Arm B) showed a significant increase only for Hb (from 7.6 ± 1.6 to 10.2 ± 0.9 g/dl) while RBCs, TSI, sFtn and IL-6 levels remained unchanged (Table 4). </plain></SENT>
<SENT sid="410" pm="."><plain>Regarding serum hepcidin concentration, it was not detectable either before or after both treatments. </plain></SENT>
<SENT sid="411" pm="."><plain>At delivery, in the bLf-treated minor β-thalassemic women, in addition to a significant decrease of IL-6 (from 25 ± 8 to 5 ± 4 pg/ml), a significant increase of Hb (from 7.8 ± 1.3 to 11.9 ± 0.7 g/dl) as well as a remarkable increase of both TSI (from 54 ± 17 to 87 ± 16 μg/dl) and sFtn (from 23 ± 5 to 34 ± 6 ng/ml) were observed (Table 5). </plain></SENT>
<SENT sid="412" pm="."><plain>Conversely, in ferrous sulfate-treated minor β-thalassemic women, excepted for Hb concentration, no increase of other hematological parameters was detected (Table 5). </plain></SENT>
</text></p><p><text><SENT sid="413" pm="."><plain>As shown in Table 6, HT pregnant women treated for 30 days with bLf (Arm C) showed a significant increase of RBCs (from 3,750 ± 127 × 103 to 4,354 ± 198 × 103), Hb (from 10.6 ± 0.4 to 12.2 ± 0.4 g/dl), TSI (from 36 ± 11 to 63 ± 9 μg/dl) and a slight increase of sFtn (from 11 ± 6 to 18 ± 2 ng/ml). </plain></SENT>
<SENT sid="414" pm="."><plain>These women presented high basal levels of IL-6 (89 ± 8 pg/ml) and hepcidin (115 ± 23 ng/ml) which were both significantly reduced (58 ± 6 pg/ml and 65 ± 10 ng/ml, respectively) already after 30 days of bLf treatment. </plain></SENT>
<SENT sid="415" pm="."><plain>Conversely, HT pregnant women treated for 30 days with ferrous sulfate (Arm D) showed a trend (p &gt; 0.005), yet not significant, toward an increase of RBCs (from 3,650 ± 163 × 103 to 3,960 ± 230 × 103) and Hb (from 10.8 ± 0.8 to 11.3 ± 1.1 g/dl). </plain></SENT>
<SENT sid="416" pm="."><plain>Of note, both IL-6 and hepcidin levels do not show any change after the treatment. </plain></SENT>
</text></p><p><text><SENT sid="417" pm="."><plain>At delivery, the bLf-treated HT women showed significant increases in all hematological values, such as RBCs (from 3,750 ± 127 × 103 to 4,482 ± 147 × 103), Hb (from 10.6 ± 0.4 to 12.7 ± 0.5 g/dl), TSI (from 36 ± 11 to 85 ± 10 μg/dl) and sFtn (from 11 ± 6 to 31 ± 3 ng/ml), as well as a significant decrease in both IL-6 and hepcidin levels (from 89 ± 8 to 50 ± 5 pg/ml and from 115 ± 23 to 65 ± 10 ng/ml, respectively). </plain></SENT>
<SENT sid="418" pm="."><plain>Conversely, HT women treated with ferrous sulfate management, showed no significant difference in any parameter evaluated compared to those obtained before the treatment (Table 7). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="419" pm="."><plain>Fetus and new-born outcomes </plain></SENT>
</text></title><p><text><SENT sid="420" pm="."><plain>The adverse effects of bLf and ferrous sulfate treatments on fetuses were monitored through ultrasonographic measurements of intrauterine growth and by the detection of amniotic fluid amount, expressed as AFI (39). </plain></SENT>
<SENT sid="421" pm="."><plain>No growth restriction was observed for any fetus. </plain></SENT>
<SENT sid="422" pm="."><plain>The AFI ranged from 13.4 ± 1.6 mean values at 34 weeks to 10.5 ± 2.3 mean values at 40 weeks. </plain></SENT>
<SENT sid="423" pm="."><plain>It is interesting to note that all the values were within 8 to 24 cm range, which is accepted and established as normal range for AFI values (42). </plain></SENT>
</text></p><p><text><SENT sid="424" pm="."><plain>The adverse effects on new-born were checked by new-born weight and APGAR score values. </plain></SENT>
<SENT sid="425" pm="."><plain>For both treatments, the new-born weight ranged among mean values corresponding to 2,950 ± 427 g for female and 3,478 ± 256 g for male. </plain></SENT>
<SENT sid="426" pm="."><plain>The APGAR score corresponded to range values of 8–10 for both sex, indicating new-born well-being. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="427" pm="."><plain>Efficacy of bovine lactoferrin treatment in pregnant women affected by various pathologies against anemia </plain></SENT>
</text></title><p><text><SENT sid="428" pm="."><plain>Table 8 presents 20 anemic pregnant women affected by different pathologies including also 3 HT twin pregnancies. </plain></SENT>
<SENT sid="429" pm="."><plain>The treatment based on bLf oral administration appeared reasonably efficient in treating anemia by increasing both Hb and TSI concentrations. </plain></SENT>
<SENT sid="430" pm="."><plain>Even if the other hematological parameters were not evaluated, bLf is efficient in increasing these two parameters related to anemia. </plain></SENT>
<SENT sid="431" pm="."><plain>Interestingly, 9 patients suffering from epilepsy showed an increase of about 2- or 3-fold of TSI concentration and more than 1 g/dl of Hb. </plain></SENT>
<SENT sid="432" pm="."><plain>In 3 pregnant women affected by insulin resistance diabetes type 2, bLf intervention showed an increase of both Hb and TSI similarly to that observed in 3 pregnancies affected by Crohn's disease. </plain></SENT>
<SENT sid="433" pm="."><plain>The efficacy of bLf oral administration has been also observed in 2 women with hypertension during the gestation. </plain></SENT>
<SENT sid="434" pm="."><plain>Of note, a great efficacy has been also observed in 3 HT twin pregnancies treated with 100 mg bLf three times a day before meals (instead of two times a day usually applied). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T8" position="float"><label>Table 8</label><caption><p><text><SENT sid="435" pm="."><plain>Mean values ± SD of hemoglobin and total serum iron of anemic pregnant women suffering from different pathologies treated for 30 days with bovine lactoferrin. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>No of women </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>Pathology </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>Age (year) </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>Week of pregnancy </plain></SENT>
</text></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="440" pm="."><plain>Hb (g/dl) </plain></SENT>
</text></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="441" pm="."><plain>TSI (μg/dl) </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>After 30 days </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>After 30 days </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>9 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>Epilepsy </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>33 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>17 ± 6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>11.1 ± 0.6 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>12.7 ± 0.4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>42 ± 16 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>111 ± 24 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>Insulin resistance diabetes type 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>35 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>28 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>10.4 ± 0.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>11.4 ± 0.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>33 ± 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>56 ± 11 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>Crohn's disease </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>31 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>29 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>9.4 ± 1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>10.6 ± 0.5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>57 ± 7 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>67 ± 8 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>2 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>Hypertension </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>34 ± 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>24 ± 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>10.7 ± 0.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>11.4 ± 0.1 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>35 ± 5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>70 ± 14 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>HT twin </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>33 ± 2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>25 ± 8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>10.5 ± 0.5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>11.6 ± 0.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>47 ± 14 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>99 ± 13 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="486" pm="."><plain>Hb, hemoglobin; TSI, total serum iron. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag></sec><sec><title><text><SENT sid="487" pm="."><plain>Efficacy of bovine lactoferrin vs. ferrous sulfate treatment in women of child-bearing age against anemia and AI </plain></SENT>
</text></title><p><text><SENT sid="488" pm="."><plain>Minor β-thalassemic women of child-bearing age treated for 30 days with bLf oral administration (Arm E) showed a remarkable, yet not significant, increase of both RBCs (from 4,280 ± 484 × 103 to 4,990 ± 323 × 103) and TSI (from 43 ± 11 to 84 ± 11 μg/dl). </plain></SENT>
<SENT sid="489" pm="."><plain>Moreover, slight increases in Hb (10.2 ± 0.8 to 11.3 ± 0.9 g/dl) and sFtn (from 18 ± 3 to 26 ± 5 ng/ml) levels as well as a decrease of serum IL-6 (from 24 ± 12 to 13 ± 8 pg/ml) concentration have been observed (Table 9). </plain></SENT>
<SENT sid="490" pm="."><plain>Conversely, no parameter was modified after ferrous sulfate treatment (Arm F). </plain></SENT>
<SENT sid="491" pm="."><plain>In addition, as observed in minor β-thalassemic pregnancies, hepcidin concentrations in minor β-thalassemic women of child-bearing age was not detectable (&lt;1 ng/ml). </plain></SENT>
<SENT sid="492" pm="."><plain>Both bLf and ferrous sulfate interventions did not exert any effect on hepcidin synthesis (Table 9). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T9" position="float"><label>Table 9</label><caption><p><text><SENT sid="493" pm="."><plain>Hematological parameters, serum IL-6 and hepcidin mean values ± SD of anemic minor β-thalassemic women of child-bearing age treated with bovine lactoferrin (Arm E) or with ferrous sulfate (Arm F), before and after 30 days of treatment. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="4" rowspan="1"><text><SENT sid="494" pm="."><plain>Minor β-thalassemic women </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="495" pm="."><plain>Arm E </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="496" pm="."><plain>Arm F </plain></SENT>
</text></th></tr><tr><th valign="top" style="border-bottom: thin solid #000000;" align="left" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>No of women completing the study Treatment </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="498" pm="."><plain>5 </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="499" pm="."><plain>4 </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="500" pm="."><plain>Bovine lactoferrin </plain></SENT>
</text></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="501" pm="."><plain>Ferrous sulfate </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>After 30 days </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>After 30 days </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>Red blood cells × 103 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain>4, 280±484 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>4, 990±323 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain>4, 294±510 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>4, 460±315 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>Hemoglobin (g/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain>10.2 ± 0.8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="513" pm="."><plain>11.3 ± 0.9 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="514" pm="."><plain>11.0 ± 1.8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="515" pm="."><plain>12.2 ± 1.3 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="516" pm="."><plain>Total serum iron (μg/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>43 ± 11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>84 ± 11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="519" pm="."><plain>39 ± 11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="520" pm="."><plain>40 ± 15 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>Serum ferritin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>18 ± 3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain>26 ± 5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="524" pm="."><plain>12 ± 7 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="525" pm="."><plain>15 ± 5 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="526" pm="."><plain>Serum IL-6 (pg/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="527" pm="."><plain>24 ± 12 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="528" pm="."><plain>13 ± 8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="529" pm="."><plain>26 ± 14 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="530" pm="."><plain>32 ± 11 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="531" pm="."><plain>Hepcidin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="532" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="533" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="534" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="535" pm="."><plain>&lt;1.0 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="536" pm="."><plain>Regarding HT women of child-bearing age, bLf treatment (Arm G) significantly increased the number of RBCs (from 3,664 ± 205 × 103 to 4,280 ± 187 × 103) and the concentration of Hb (10.4 ± 0.8 to 12.5 ± 0.6 g/dl), TSI (from 36 ± 10 to 90 ± 12 μg/dl) and sFtn (from 9 ± 3 to 22 ± 6 ng/ml). </plain></SENT>
<SENT sid="537" pm="."><plain>Furthermore, this treatment also significantly decreased serum IL-6 and hepcidin synthesis (Table 10), similarly to that observed in HT pregnancies. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T10" position="float"><label>Table 10</label><caption><p><text><SENT sid="538" pm="."><plain>Hematological parameters, serum IL-6 and hepcidin mean values ± SD of HT women of child-bearing age, suffering from AI treated with bovine lactoferrin (Arm G) or with ferrous sulfate (Arm H), before and after 30 days of treatment. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="4" rowspan="1"><text><SENT sid="539" pm="."><plain>HT women </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="540" pm="."><plain>Arm G </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="541" pm="."><plain>Arm H </plain></SENT>
</text></th></tr><tr><th valign="top" style="border-bottom: thin solid #000000;" align="left" rowspan="1" colspan="1"><text><SENT sid="542" pm="."><plain>No of women completing the study Treatment </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="543" pm="."><plain>41 </plain></SENT>
</text></th><th valign="top" align="center" colspan="2" rowspan="1"><text><SENT sid="544" pm="."><plain>32 </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="545" pm="."><plain>Bovine lactoferrin </plain></SENT>
</text></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" colspan="2" rowspan="1"><text><SENT sid="546" pm="."><plain>Ferrous sulfate </plain></SENT>
</text></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="547" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="548" pm="."><plain>After 30 days </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="549" pm="."><plain>Before </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="550" pm="."><plain>After 30 days </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="551" pm="."><plain>Red blood cells × 103 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="552" pm="."><plain>3, 664±205 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="553" pm="."><plain>4, 280±187* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="554" pm="."><plain>4, 088±289 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="555" pm="."><plain>3, 989±265 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="556" pm="."><plain>Hemoglobin (g/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="557" pm="."><plain>10.4 ± 0.8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="558" pm="."><plain>12.5 ± 0.6* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="559" pm="."><plain>11.4 ± 0.8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="560" pm="."><plain>11.8 ± 1.0 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="561" pm="."><plain>Total serum iron (μg/dl) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="562" pm="."><plain>36 ± 10 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="563" pm="."><plain>90 ± 12* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="564" pm="."><plain>40 ± 12 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="565" pm="."><plain>45 ± 15 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="566" pm="."><plain>Serum ferritin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="567" pm="."><plain>9 ± 3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="568" pm="."><plain>22 ± 6* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="569" pm="."><plain>11 ± 5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="570" pm="."><plain>14 ± 6 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="571" pm="."><plain>Serum IL-6 (pg/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="572" pm="."><plain>45 ± 9 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="573" pm="."><plain>9 ± 8* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="574" pm="."><plain>41 ± 13 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="575" pm="."><plain>49 ± 8 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="576" pm="."><plain>Hepcidin (ng/ml) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="577" pm="."><plain>100 ± 8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="578" pm="."><plain>60 ± 18* </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="579" pm="."><plain>104 ± 10 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="580" pm="."><plain>100 ± 15 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="TN5"><label>*</label><p><text><SENT sid="581" pm="."><plain>Significantly different from before treatment (p &lt; 0.001). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="582" pm="."><plain>Conversely, ferrous sulfate treatment in HT women of child-bearing age (Arm H) showed only a slight, yet not significant, increase for Hb and TSI. </plain></SENT>
<SENT sid="583" pm="."><plain>Of note, both IL-6 and hepcidin levels do not show any change after the treatment (Table 10). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s4"><title><text><SENT sid="584" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="585" pm="."><plain>Recently, Lf, a multifunctional glycoprotein, endowed with potent immune-modulatory properties, is emerging as an important component of iron and inflammatory homeostasis machinery (4, 23). </plain></SENT>
</text></p><p><text><SENT sid="586" pm="."><plain>In 2006, by designing our first clinical trial on the effect of 30 days of bLf oral administration (100 mg two times a day before meals) compared with oral administration of ferrous sulfate (329.7 mg once a day during the meal) in anemic pregnant women, surprising results were obtained (36). </plain></SENT>
<SENT sid="587" pm="."><plain>Pregnant women receiving iron saturated bLf (20–30%) two times a day, absorbed 70–84 μg/day of elemental iron, respectively, through enterocytes. </plain></SENT>
<SENT sid="588" pm="."><plain>Although the concentration of iron supplemented by bLf is very far from that required daily (1–2 mg), a significant increase of the concentration of Hb and TSI was detected 30 days after treatment. </plain></SENT>
<SENT sid="589" pm="."><plain>Later on, in our subsequent clinical trials carried out on pregnant women suffering from anemia and AI, bLf treatment induced, in addition to Hb and TSI levels, a significant improvement of the number of RBCs and sFtn concentrations. </plain></SENT>
<SENT sid="590" pm="."><plain>Interestingly, a significant decrease of serum levels of IL-6, considered a key pro-inflammatory cytokine in iron homeostasis, was observed (4, 29, 37, 38). </plain></SENT>
<SENT sid="591" pm="."><plain>Differently from bLf, ferrous sulfate was ineffective in treating anemia and AI even if iron supply was a 1,000-fold higher than that furnished by bLf (about 100 mg/day vs. about 80 μg/day). </plain></SENT>
<SENT sid="592" pm="."><plain>Moreover, ferrous sulfate does not decrease the levels of serum IL-6 (4, 29, 36–38). </plain></SENT>
<SENT sid="593" pm="."><plain>Therefore, even if the mechanism by which bLf exerts its anti-inflammatory activity is still under debate, there are strong evidences that bLf efficacy in treating anemia and AI is not linked to a direct iron supplementation, but to a more complex mechanism involving this protein in decreasing IL-6 and modulating hepcidin and Fpn, the most important iron homeostasis actors, both regulated by IL-6 (23, 44). </plain></SENT>
</text></p><p><text><SENT sid="594" pm="."><plain>In this respect, our group has recently demonstrated that bLf is able to revert the iron disorders in human inflamed-macrophages. </plain></SENT>
<SENT sid="595" pm="."><plain>In particular, bLf, by exerting its anti-inflammatory activity vs. IL-6 synthesis, determines the up-regulation of Fpn expression, thus leading to an efficient recovery of iron efflux from cells to blood (8, 9). </plain></SENT>
</text></p><p><text><SENT sid="596" pm="."><plain>The bLf anti-inflammatory activity has been explained by the discovery of its nuclear localization thus suggesting that this molecule may be involved in the transcriptional regulation of some genes of host inflammatory response (4, 45, 46). </plain></SENT>
<SENT sid="597" pm="."><plain>Lf is, therefore, a key element not only in the host defense system (47–49) but also a pivotal glycoprotein able to treat anemia through the inhibition of the inflammatory response, especially in pregnant women affected by HT (29). </plain></SENT>
</text></p><p><text><SENT sid="598" pm="."><plain>Here, we present novel and promising results on the efficacy and safety of bLf treatment in curing anemia and AI in minor β-thalassemic and HT pregnant and non-pregnant women, respectively, as well as anemia in pregnant women suffering from various pathologies. </plain></SENT>
</text></p><p><text><SENT sid="599" pm="."><plain>For the first time, the serum hepcidin has been detected in minor β-thalassemic and HT pregnant and non-pregnant women and correlated with all the other clinical parameters evaluated before and after bLf or ferrous sulfate management. </plain></SENT>
</text></p><p><text><SENT sid="600" pm="."><plain>Furthermore, we confirm the results obtained in our previous clinical trials on HT pregnancies (29) through the enrolment of additional 70 HT pregnant women and 79 HT women of child-bearing age. </plain></SENT>
</text></p><p><text><SENT sid="601" pm="."><plain>Overall, both HT pregnant and non-pregnant women, after 30 days of bLf treatment, show a significant increase of RBCs, Hb, TSI and sFtn. </plain></SENT>
<SENT sid="602" pm="."><plain>Of note, bLf treatment also significantly reduces IL-6 and hepcidin levels compared to the high basal concentrations (Table 6 Arm C and Table 10 Arm G). </plain></SENT>
<SENT sid="603" pm="."><plain>The effect of bLf treatment, leading to the down-regulation of hepcidin synthesis, should be considered as a signal of a regulatory mechanism exerted by bLf to avoid the pathological intracellular iron overload, thus restoring the physiological iron export to blood through Fpn up-regulation. </plain></SENT>
<SENT sid="604" pm="."><plain>In fact, the persistence of high levels of IL-6 and hepcidin would inhibit the iron export through the down-regulation and degradation of Fpn, causing an unsafe intracellular iron overload, specially in those cells involved in iron absorption and recycle, such as enterocytes and macrophages, respectively. </plain></SENT>
<SENT sid="605" pm="."><plain>As matter of fact, inflammation-mediated iron retention in macrophages determines the most pivotal cause of AI establishment and maintenance. </plain></SENT>
<SENT sid="606" pm="."><plain>Indeed, upon inflammatory stimulation, macrophages polarize in a sub-population, namely M1, characterized by production of pro-inflammatory cytokines, such as IL-6, the down-regulation of Fpn and up-regulation of cytosolic Ftn, leading to the block of iron recycling to blood from senescent erythrocytes, the major iron source for the body (50, 51). </plain></SENT>
<SENT sid="607" pm="."><plain>The current finding that bLf, through its anti-inflammatory activity, is able to revert this unsafe condition restoring the physiological iron export from macrophages to blood can be considered an actual molecular mechanism to explain the bLf efficacy, iron independent, in treating AI in HT pregnant and non-pregnant women. </plain></SENT>
</text></p><p><text><SENT sid="608" pm="."><plain>Conversely, ferrous sulfate treatment in HT pregnant and non-pregnant women shows a trend toward an increase in only RBCs and Hb. </plain></SENT>
<SENT sid="609" pm="."><plain>Moreover, this management fails in decreasing both IL-6 and hepcidin levels (Table 6 Arm D and Table 10 Arm H). </plain></SENT>
<SENT sid="610" pm="."><plain>The failure of ferrous sulfate treatment could be explained by its inability to modulate hepcidin or Fpn expression in a direct way (never demonstrated) or indirectly through the inhibition of IL-6 synthesis (never demonstrated). </plain></SENT>
</text></p><p><text><SENT sid="611" pm="."><plain>The efficacy of bLf oral administration in treating anemia was also tested on pregnant women suffering from various pathologies. </plain></SENT>
<SENT sid="612" pm="."><plain>In these pregnant women bLf management appears effective (Table 8). </plain></SENT>
<SENT sid="613" pm="."><plain>Of note, regarding pregnant women affected by epilepsy, bLf treatment greatly increases TSI concentration (about 2- or 3-fold) and Hb (about 1 g/dl). </plain></SENT>
<SENT sid="614" pm="."><plain>The encouraging results were also obtained on HT twin pregnancies where the management has required an additional oral administration of bLf (100 mg three times a day). </plain></SENT>
</text></p><p><text><SENT sid="615" pm="."><plain>In this interventional study, the efficacy of bLf oral administration has been also demonstrated in anemic pregnant and non-pregnant women affected by minor β-thalassemia, an inherited autosomal recessive Hb disorder characterized by reduced synthesis of the β-chain of Hb (24). </plain></SENT>
</text></p><p><text><SENT sid="616" pm="."><plain>Even if the number of enrolled minor β-thalassemic women is low and does not allow to obtain conclusive and convincing results, bLf treatment demonstrates a simultaneous decrease in IL-6 and an increase in TSI both in pregnant and non-pregnant women even if at different extent (Table 4 Arm A and Table 9 Arm E). </plain></SENT>
<SENT sid="617" pm="."><plain>Remarkably, in these subjects hepcidin is not detectable both before and after bLf management. </plain></SENT>
<SENT sid="618" pm="."><plain>This observation supports the hypothesis that bLf, independently from hepcidin but dependently from IL-6 down-regulation, may act as a positive regulator of Fpn, thus increasing iron efflux to blood. </plain></SENT>
<SENT sid="619" pm="."><plain>This potential mechanism is indeed supported by the increase of TSI values in all minor β-thalassemic women already after 30 days of bLf treatment (Table 4 Arm A and Table 9 Arm E). </plain></SENT>
</text></p><p><text><SENT sid="620" pm="."><plain>Similar to bLf, ferrous sulfate treatment in minor β-thalassemic pregnant and non-pregnant women leads to an increase of Hb concentration while, conversely to bLf, it does not influence IL-6 synthesis (Table 4 Arm B and Table 9 Arm F). </plain></SENT>
<SENT sid="621" pm="."><plain>Regarding serum hepcidin concentration, it was not detectable before and after ferrous sulfate intervention (Table 4 Arm B and Table 9 Arm F). </plain></SENT>
<SENT sid="622" pm="."><plain>Taken together all the results, alternatively to the hepcidin agonists or antagonists as therapeutic tools (20), bLf oral administration can be considered as a first promising compound in treating anemia through the decrease of both IL-6 and hepcidin thus restoring Fpn-mediated iron export from cells to blood in an hepcidin dependent or independent way. </plain></SENT>
</text></p><p><text><SENT sid="623" pm="."><plain>Even if the number of patients is low and further investigations are required, these results highlight and support the importance of bLf oral administration in the treatment of the iron and inflammatory homeostasis disorders. </plain></SENT>
</text></p></sec></SecTag><SecTag type="AUTH_CONT"><sec id="s5"><title><text><SENT sid="624" pm="."><plain>Author contributions </plain></SENT>
</text></title><p><text><SENT sid="625" pm="."><plain>PV and RP conceived, designed the clinical trial and wrote the first draft of manuscript. </plain></SENT>
<SENT sid="626" pm="."><plain>ML, LR, AC, and MC performed the laboratory analysis, analyzed the data, edited the manuscript, and prepared the figures and tables. </plain></SENT>
<SENT sid="627" pm="."><plain>All authors read and approved the final version. </plain></SENT>
</text></p><sec><title><text><SENT sid="628" pm="."><plain>Conflict of interest statement </plain></SENT>
</text></title><p><text><SENT sid="629" pm="."><plain>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="630" pm="."><plain>This work was granted by Sapienza University of Rome Funds to PV. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="631" pm="."><plain>1.BothwellTH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. </plain></SENT>
<SENT sid="632" pm="."><plain>(2000) 72:257S−64S. 10.1093/ajcn/72.1.257S<?supplied-pmid 10871591?>10871591 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="633" pm="."><plain>2.McLeanECogswellMEgliIWojdylaDde BenoistB. Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993–2005. Public Health Nutr. </plain></SENT>
<SENT sid="634" pm="."><plain>(2009) 12:444–4. 10.1017/S1368980008002401<?supplied-pmid 18498676?>18498676 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="635" pm="."><plain>3.GisbertJPGomollónF An update on iron physiology. World J Gastroenterol. </plain></SENT>
<SENT sid="636" pm="."><plain>(2009) 15:4617–26. 10.3748/wjg.15.461719787824 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="637" pm="."><plain>4.PaesanoRNataliziTBerluttiFValentiP. Body iron delocalization: the serious drawback in iron disorders in both developing and developed countries. Pathog Glob Health (2012) 106:200–16. 10.1179/2047773212Y.0000000043<?supplied-pmid 23265420?>23265420 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="638" pm="."><plain>5.GanzT Iron and infection. Int J Hematol. </plain></SENT>
<SENT sid="639" pm="."><plain>(2018) 107:7–15. 10.1007/s12185-017-2366-229147843 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="640" pm="."><plain>6.KrauseANeitzSMagertHJSchulzAForssmannWGSchulz-KnappeP. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. </plain></SENT>
<SENT sid="641" pm="."><plain>(2000) 480:147–50. 10.1016/S0014-5793(00)01920-7<?supplied-pmid 11034317?>11034317 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="642" pm="."><plain>7.DonovanALimaCAPinkusJLPinkusGSZonLIRobineS. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. </plain></SENT>
<SENT sid="643" pm="."><plain>(2005) 1:191–200. 10.1016/j.cmet.2005.01.003<?supplied-pmid 16054062?>16054062 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="644" pm="."><plain>8.CutoneAFrioniABerluttiFValentiPMusciGBonaccorsi di PattiMC. Lactoferrin prevents LPS-induced decrease of the iron exporter ferroportin in human monocytes/macrophages. Biometals (2014) 27:807–13. 10.1007/s10534-014-9742-7<?supplied-pmid 24793588?>24793588 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="645" pm="."><plain>9.CutoneARosaLLepantoMSScottiMJBerluttiFBonaccorsi di PattiMC Lactoferrin efficiently counteracts the inflammation-induced changes of the iron homeostasis system in macrophages. Front Immunol. </plain></SENT>
<SENT sid="646" pm="."><plain>(2017) 15:705 10.3389/fimmu.2017.00705 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="647" pm="."><plain>10.ParkCHValoreEVWaringAJGanzT. Hepcidin a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. </plain></SENT>
<SENT sid="648" pm="."><plain>(2001) 276:7806–10. 10.1074/jbc.M008922200<?supplied-pmid 11113131?>11113131 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="649" pm="."><plain>11.HunterHNFultonDBGanzTVogelHJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem. </plain></SENT>
<SENT sid="650" pm="."><plain>(2002) 277:37597–603. 10.1074/jbc.M205305200<?supplied-pmid 12138110?>12138110 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="651" pm="."><plain>12.NemethERiveraSGabayanVKellerCTaudorfSPedersenBK. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Investig. </plain></SENT>
<SENT sid="652" pm="."><plain>(2004) 113:1271–6. 10.1172/JCI20945<?supplied-pmid 15124018?>15124018 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="653" pm="."><plain>13.LeePPengHGelbartTWangLBeutlerE. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA. (2005) 102:1906–10. 10.1073/pnas.0409808102<?supplied-pmid 15684062?>15684062 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="654" pm="."><plain>14.WrightingDMAndrewsNC. Interleukin-6 induces hepcidin expression through STAT3. Blood (2006) 108:3204–9. 10.1182/blood-2006-06-027631<?supplied-pmid 16835372?>16835372 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="655" pm="."><plain>15.Verga FalzacappaMVVujic SpasicMKesslerRStolteJHentzeMWMuckenthalerMU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood (2007) 109:353–8. 10.1182/blood-2006-07-033969<?supplied-pmid 16946298?>16946298 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="656" pm="."><plain>16.CoffeyRGanzT. Iron homeostasis—an anthropocentric perspective. J Biol Chem. (2017) 292:12727–34. 10.1074/jbc.R117.781823<?supplied-pmid 28615456?>28615456 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="657" pm="."><plain>17.AndrewsNC. Disorders of iron metabolism. N Engl J Med. (1999) 341:1986–95. 10.1056/NEJM199912233412607<?supplied-pmid 10607817?>10607817 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="658" pm="."><plain>18.FrazerDMAndersonGJ. The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol Dis. </plain></SENT>
<SENT sid="659" pm="."><plain>(2003) 30:288–97. 10.1016/S1079-9796(03)00039-1<?supplied-pmid 12737947?>12737947 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="660" pm="."><plain>19.QiaoBSugiantoPFungEDel-Castillo-RuedaAMoran-JimenezMJGanzT. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. </plain></SENT>
<SENT sid="661" pm="."><plain>(2012) 15:918–24. 10.1016/j.cmet.2012.03.018<?supplied-pmid 22682227?>22682227 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="662" pm="."><plain>20.CasuCNemethERivellaS. Hepcidin agonists as therapeutic tools. Blood (2018) 131:1790–4. 10.1182/blood-2017-11-737411<?supplied-pmid 29523504?>29523504 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="663" pm="."><plain>21.WillemetzABeattySRicherERubioAAuriacAMilkereitRJ. Iron- and hepcidin-independent downregulation of the iron exporter ferroportin in macrophages during salmonella infection. Front Immunol. </plain></SENT>
<SENT sid="664" pm="."><plain>(2017) 8:498. 10.3389/fimmu.2017.00498<?supplied-pmid 28507548?>28507548 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="665" pm="."><plain>22.Wessling-ResnickM. Iron homeostasis and the inflammatory response. Annu Rev Nutr. </plain></SENT>
<SENT sid="666" pm="."><plain>(2010) 30:105–22. 10.1146/annurev.nutr.012809.104804<?supplied-pmid 20420524?>20420524 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="667" pm="."><plain>23.RosaLCutoneALepantoMSPaesanoRValentiP. Lactoferrin: a natural glycoprotein involved in iron and inflammatory homeostasis. Int J Mol Sci. </plain></SENT>
<SENT sid="668" pm="."><plain>(2017) 18:E1985. 10.3390/ijms18091985<?supplied-pmid 28914813?>28914813 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="669" pm="."><plain>24.GalanelloROrigaR Beta-thalassemia. Orphanet J Rare Dis. </plain></SENT>
<SENT sid="670" pm="."><plain>(2010) 5:11 10.1186/1750-1172-5-1120492708 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="671" pm="."><plain>25.GulinoFAVitaleSGFauziaMCianciSPafumiCPalumboMA. Beta-thalassemia major and pregnancy. Bratisl Lek Listy. </plain></SENT>
<SENT sid="672" pm="."><plain>(2013) 114:523–5. 10.4149/BLL_2013_109<?supplied-pmid 24020709?>24020709 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="673" pm="."><plain>26.OrigaRPigaAQuartaGForniGLLongoFMelpignanoA. Pregnancy and β-thalassemia: an Italian multicenter experience. Haematologica (2010) 95:376–81. 10.3324/haematol.2009.012393<?supplied-pmid 19903676?>19903676 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="674" pm="."><plain>27.PratummoKJetsrisuparbAFucharoenSTripataraA. Hepcidin expression from monocyte of splenectomized and non-splenectomized patients with HbE-β-thalassemia. Hematology (2014) 19:175–80. 10.1179/1607845413Y.0000000110<?supplied-pmid 23905873?>23905873 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="675" pm="."><plain>28.El-RasheidyFHEssaESMahmoudAANada Ael-W. Elevated serum adiponectin is related to elevated serum ferritin and interleukin-6 in β-thalassaemia major children. J Pediatr Endocrinol Metab. (2016) 29:953–8. 10.1515/jpem-2016-0014<?supplied-pmid 27235671?>27235671 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="676" pm="."><plain>29.PaesanoRPacificiEBenedettiSBerluttiFFrioniAPolimeniA. Safety and efficacy of lactoferrin versus ferrous sulphate in curing iron deficiency and iron deficiency anaemia in hereditary thrombophilia pregnant women: an interventional study. BioMetals (2014) 27:999–1006. 10.1007/s10534-014-9723-x<?supplied-pmid 24590680?>24590680 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="677" pm="."><plain>30.RosendaalFR. Venous thrombosis: a multicausal disease. Lancet (1999) 353:1167–73. 10.1016/S0140-6736(98)10266-0<?supplied-pmid 10209995?>10209995 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="678" pm="."><plain>31.KhanSDickermanJD Hereditary thrombophilias. Thromb J. (2006) 4:15 10.1186/1477-9560-4-1516968541 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="680" pm="."><plain>32.SzecsiPBJørgensenMKlajnbardAAndersenMRColovNPStenderS. Haemostatic reference intervals in pregnancy. Thromb Haemost. </plain></SENT>
<SENT sid="681" pm="."><plain>(2010) 103:718–27. 10.1160/TH09-10-0704<?supplied-pmid 20174768?>20174768 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="682" pm="."><plain>33.SimcoxLEOrmesherLTowerCGreerIA. Thrombophilia and pregnancy complications. Int J Mol Sci. (2015) 16:28418–28. 10.3390/ijms161226104<?supplied-pmid 26633369?>26633369 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="683" pm="."><plain>34.PoredosPJezovnikMK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol. </plain></SENT>
<SENT sid="684" pm="."><plain>(2007) 26:306–11. <?supplied-pmid 18091697?>18091697 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="685" pm="."><plain>35.ValentiPRosaLCapobiancoDLepantoMSSchiaviECutoneA. Role of lactobacilli and lactoferrin in the mucosal cervicovaginal defense. Front Immunol. </plain></SENT>
<SENT sid="686" pm="."><plain>(2018) 9:376. 10.3389/fimmu.2018.00376<?supplied-pmid 29545798?>29545798 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="687" pm="."><plain>36.PaesanoRTorciaFBerluttiFPacificiEEbanoVMoscariniM. Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol. </plain></SENT>
<SENT sid="688" pm="."><plain>(2006) 84:377–80. 10.1139/o06-040<?supplied-pmid 16936810?>16936810 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="689" pm="."><plain>37.PaesanoRPietropaoliMGessaniSValentiP. The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie. </plain></SENT>
<SENT sid="690" pm="."><plain>(2009) 91:44–51. 10.1016/j.biochi.2008.06.004<?supplied-pmid 18601971?>18601971 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="691" pm="."><plain>38.PaesanoRBerluttiFPietropaoliMGoolsbeeWPacificiEValentiP. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women. Int J Immunopathol Pharmacol. (2010) 23:577–87. 10.1177/039463201002300220<?supplied-pmid 20646353?>20646353 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="692" pm="."><plain>39.KaandorpSDi NisioMGoddijnMMiddeldorpS Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev. </plain></SENT>
<SENT sid="693" pm="."><plain>(2009) 1:CD004734 10.1002/14651858 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="694" pm="."><plain>40.BrancaleoniVDi PierroEMottaICappelliniMD Laboratory diagnosis of thalassemia. Int J Lab Hematol. (2016) 1:32–40. 10.1111/ijlh.12527 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="695" pm="."><plain>41.JacksonRHolmesKPhansalkarARodgersGM. Testing for hereditary thrombophilia: a retrospective analysis of testing referred to a national laboratory. BMC Clin Pathol. </plain></SENT>
<SENT sid="696" pm="."><plain>(2008) 8:1–7. 10.1186/1472-6890-8-3<?supplied-pmid 18384680?>18230182 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="697" pm="."><plain>42.PetrozellaLNDasheJSMcIntireDDLevenoKJ. Clinical significance of borderline amniotic fluid index and oligohydramnios in preterm pregnancy. Obstet Gynecol. </plain></SENT>
<SENT sid="698" pm="."><plain>(2011) 117:338–42. 10.1097/AOG.0b013e3182056766<?supplied-pmid 21252747?>21252747 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="699" pm="."><plain>43.RosaLCutoneALepantoMSScottiMJConteMPPaesanoR. Physico-chemical properties influence the functions and efficacy of commercial bovine lactoferrins. BioMetals (2018) 31:301–12. 10.1007/s10534-018-0092-8<?supplied-pmid 29516297?>29516297 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="700" pm="."><plain>44.Bonaccorsi di PattiMCCutoneAPolticelliFRosaLLepantoMSValentiP. The ferroportin-ceruloplasmin system and the mammalian iron homeostasis machine: regulatory pathways and the role of lactoferrin. BioMetals (2018) 31:399–414. 10.1007/s10534-018-0087-5<?supplied-pmid 29453656?>29453656 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="701" pm="."><plain>45.AshidaKSasakiHSuzukiYALönnerdalB. Cellular internalization of lactoferrin in intestinal epithelial cells. BioMetals (2004) 17:311–5. <?supplied-pmid 15222483?>15222483 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="702" pm="."><plain>46.SuzukiYAWongHAshidaKYSchryversABLönnerdalB. The N1 domain of human lactoferrin is required for internalization by Caco-2 cells and targeting to the nucleus. Biochemistry (2008) 47:10915–20. 10.1021/bi8012164<?supplied-pmid 18785755?>18785755 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="703" pm="."><plain>47.ValentiPAntoniniG. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci. </plain></SENT>
<SENT sid="704" pm="."><plain>(2005) 62:2576–87. 10.1007/s00018-005-5372-0<?supplied-pmid 16261253?>16261253 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="705" pm="."><plain>48.LegrandD. Lactoferrin a key molecule in immune and inflammatory processes. Biochem Cell Biol. </plain></SENT>
<SENT sid="706" pm="."><plain>(2012) 90:252–68. 10.1139/o11-056<?supplied-pmid 22136726?>22136726 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="707" pm="."><plain>49.WardPPPazEConneelyOM. Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci. (2005) 62:2540–8. 10.1007/s00018-005-5369-8<?supplied-pmid 16261256?>16261256 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="708" pm="."><plain>50.RecalcatiSLocatiMMariniASantambrogioPZaninottoFDe PizzoliM Differential regulation of iron homeostasis during human macro- phage polarized activation. Eur J Immunol. (2010) 40:824–35. 10.1002/eji.20093988920039303 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="709" pm="."><plain>51.CornaGCampanaLPignattiECastiglioniATagliaficoEBosurgiL. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica (2010) 95:1814–22. 10.3324/haematol.2010.023879<?supplied-pmid 20511666?>20511666 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
